Search

Displaying results 6951 - 6960 of 10000 in total
  1. Drug

    Fosifloxuridine nafalbenamide

    go.drugbank.com/drugs/DB14859
    Investigational

    Fosifloxuridine nafalbenamide is under investigation in clinical trial NCT03428958 (A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment).

  2. Drug

    Ieramilimab

    go.drugbank.com/drugs/DB16419
    Investigational

    Ieramilimab is under investigation in clinical trial NCT02460224 (Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.).

  3. Drug

    Neisseria meningitidis group A capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB15680
    ApprovedInvestigational

  4. Drug

    Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB15681
    ApprovedInvestigational

    Products: NeisVac-C Injektionssuspension in einer Fertigspritze
  5. Drug

    Ofloxacin

    go.drugbank.com/drugs/DB01165
    ApprovedInvestigational

    A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

  6. Drug

    Quavonlimab

    go.drugbank.com/drugs/DB16422
    Investigational

    Quavonlimab is under investigation in clinical trial NCT03179436 (Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)).

  7. Drug

    AP5346

    go.drugbank.com/drugs/DB04992
    Investigational

    AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer. It is being pursued by Access Pharmaceuticals, Inc.

  8. Drug

    Sulfamethizole

    go.drugbank.com/drugs/DB00576
    ApprovedVet approved

    A sulfathiazole antibacterial agent.

  9. Drug

    Efzofitimod

    go.drugbank.com/drugs/DB16453
    Investigational

    It is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states.

  10. Drug

    Reposal

    go.drugbank.com/drugs/DB13805
    Experimental

    Reposal is a barbiturate derivative invented in the 1960s in Denmark that has sedative, hypnotic and anticonvulsant properties. It was used primarily in the treatment of insomnia.